CU6 — Clarity Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$695.59m
- AU$517.34m
Brief: Clarity's U.S.-Based Cu-64 SAR-bisPSMA Trial In Prostate Cancer Opens For Recruitment
Australia Stock Exchange release from CLARITY PHARMACE : COBRA trial in prostate cancer opens for recruitment
Australia Stock Exchange release from CLARITY PHARMACE : New clinical trial collaboration in prostate cancer
Australia Stock Exchange release from CLARITY PHARMACE : Clarity - Investor Presentation 03-03-2022
Australia Stock Exchange release from CLARITY PHARMACE : Clarity Half Yearly Report
Australia Stock Exchange release from CLARITY PHARMACE : PRE_NR Ends: 16:38:33
Australia Stock Exchange release from CLARITY PHARMACE : PRE_NR Ends: 16:05:53
Australia Stock Exchange release from CLARITY PHARMACE : Half Year Accounts
Australia Stock Exchange release from CLARITY PHARMACE : PRE_NR Ends: 10:05:21
Australia Stock Exchange release from CLARITY PHARMACE : Update on China Grand Pharmaceutical and Healthcare Holdings
Australia Stock Exchange release from CLARITY PHARMACE : First patient treated in cohort 2 neuroblastoma trial
Australia Stock Exchange release from CLARITY PHARMACE : PRE_NR Ends: 09:39:47
Australia Stock Exchange release from CLARITY PHARMACE : Release of Securities from Escrow
Brief: US FDA Study May Proceed Letter For Clarity's Cu-64 Sar-Bispsma Trial In Prostate Cancer
Australia's Clarity Pharmaceuticals gains on FDA nod for cancer product trial
Brief: Clarity Pharmaceuticals Receives Confirmation From US Food And Drug Administration
Australia Stock Exchange release from CLARITY PHARMACE : US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
Australia Stock Exchange release from CLARITY PHARMACE : PRE_NR Ends: 09:55:43
Australia Stock Exchange release from CLARITY PHARMACE : Clarity receives $3.26 million R&D tax incentive refund